Oct 16, 2025 8:00am EDT bioAffinity Technologies Announces Notification of Allowance for U.S. Patent Application for Its Diagnostic Algorithm and Test Method for Lung Cancer
Oct 09, 2025 1:00pm EDT bioAffinity Technologies, Inc. Announces Closing of $1.8 Million Registered Direct Financing of Common Stock Priced At-The-Market Under Nasdaq Rules
Oct 08, 2025 3:45pm EDT bioAffinity Technologies, Inc. Announces Approximately $1.8 Million Registered Direct Financing of Common Stock Priced At-The-Market Under Nasdaq Rules
Oct 07, 2025 8:00am EDT bioAffinity Technologies Reports Record Growth in CyPath® Lung Test Volume for Third Quarter 2025
Sep 26, 2025 8:00am EDT bioAffinity Technologies Adds to Growing Number of Case Studies Demonstrating Clinical Value of CyPath® Lung
Sep 17, 2025 8:15am EDT bioAffinity Technologies Announces 1-for-30 Reverse Stock Split Effective at the Open of Trading on September 19, 2025
Sep 09, 2025 8:00am EDT Case Study: CyPath® Lung Identifies Lung Cancer in Patient with Difficult-to-Diagnose Ground-Glass Pulmonary Nodules
